BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR
Determine BRAF V600E mutation status in patients with solid tumors to select candidates for targeted therapy with kinase inhibitors (BRAF and/or MEK). Monitor response to therapy and disease progression in patients carrying BRAF V600E mutation.
New York DOH Approval Status
Whole blood in two 10mL Cell-Free DNA (cfDNA) BCT Tubes. Specimens must be collected using the Kit, Cell-Free DNA Blood Collection Tube (ARUP Supply #52358) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.
Transport 20 mL whole blood in cfDNA BCT Tubes. (Min: 16 mL)
FFPE tissue. Whole blood collected in non-cfDNA BCT tubes.
Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
Polymerase Chain Reaction
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*
|Component Chart Name
|BRAF V600E cfDNA Result
|BRAF V600E cfDNA Mutant Allele Frequency
|BRAF V600E cfDNA Mutant copies/mL